FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149... -- EAST HANOVER, N.J., March 8, 2011 /PRNewswire/ --
Links shared publicly online about this topic.
- 453total visits
FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149... -- EAST HANOVER, N.J., March 8, 2011 /PRNewswire/ --
FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD. - Phase III program demonstrated significant improvement in lung function lasting for 24 hours and supported safety and tolerability profile of QAB149 - COPD is a progressive and life-threatening lung
View full resource at prnewswire.com
Tags: Lung, COPD, FDA, Novartis, Safety
Most Recently Shared on March 9, 2011 at 3:42 am By:
FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator Indacaterol http://t.co/E2ttppR
Advertisement
